論文業績

2025年

2024年

  1. Hirano A, Kadoya H, Takasu M, Iwakura T, Kajimoto E, Tatsugawa R, Matsuura T, Kurumatani H, Yamamoto T, Kidokoro K, Kishi S, Nagasu H, Sasaki T, Kashihara N.：Effects of Beraprost on Intestinal Microcirculation and Barrier Function in a Mouse Model of Renal Failure.Microcirculation. 31(8):e12889, 2024
  2. Kajimoto E, Nagasu H, Takasu M, Kishi S, Wada M, Tatsugawa R, Hirano A, Iwakura T, Umeno R, Wada Y, Itano S, Kadoya H, Kidokoro K, Sasaki T, Kashihara N.：ASK-1 activation exacerbates kidney dysfunction via increment of glomerular permeability and accelerates cellular aging in diabetic kidney disease model mice.Sci Rep. 14(1):26438, 2024
  3. Shimamoto S, Nakahara T, Yamada S, Nagasu H, Kishi S, Nakashima N, Tsuruya K, Okada H, Tamura K, Narita I, Maruyama S, Yano Y, Yokoo T, Wada T, Wada J, Kanda E, Kataoka H, Nangaku M, Kashihara N, Nakano T.：Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex).Sci Rep. 14(1):27481, 2024
  4. Kishi S, Nagasu H, Kidokoro K, Kashihara N.：Oxidative stress and the role of redox signalling in chronic kidney disease.Nat Rev Nephrol. 20(2):101-119, 2024
  5. Sugawara Y, Kanda E, Hamano T, Itano S, Okada H, Tomori K, Watanabe Y, Asakura W, Isaka Y, Iseki K, Usui T, Suzuki Y, Tanaka M, Nishimura R, Fukami K, Matsushita K, Wada J, Watada H, Ueki K, Kashihara N, Nangaku M; Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease.：Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.Clin Exp Nephrol. 28(9):847-865, 2024
  6. Wada Y, Kidokoro K, Kondo M, Tokuyama A, Kadoya H, Nagasu H, Kanda E, Sasaki T, Cherney DZI, Kashihara N.：Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.Kidney Int. 106(3):408-418, 2024
  7. Kishi S, Kadoya H, Kashihara N.; Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease.：Treatment of chronic kidney disease in older populations.Nat Rev Nephrol. 20(9):586-602, 2024
  8. Kishi S, Nakashima T, Goto T, Nagasu H, Brooks CR, Okada H, Tamura K, Nakano T, Narita I, Maruyama S, Yano Y, Yokoo T, Wada T, Wada J, Nangaku M, Kashihara N.：TAssociation of serum magnesium levels with renal prognosis in patients with chronic kidney disease.Clin Exp Nephrol. 28(8):784-792, 2024
  9. Kanaoka T, Wakui H, Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Nakagawa N, Wada J, Tsuruya K, Nakano T, Maruyama S, Wada T, Konishi M, Nagahiro T, Yamagata K, Narita I, Yanagita M, Terada Y, Araki S, Emoto M, Okada H, Isaka Y, Suzuki Y, Yokoo T, Kataoka H, Kanda E, Kashihara N, Tamura K; J-CKD-DB investigators.：Factors affecting the sodium-glucose cotransporter2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidneydisease with type 2 diabetes: The Japan Chronic Kidney Disease Database.Diabetes Obes Metab. 26(7):2905-2914, 2024
  10. Nyma Z, Kitaoka K, Yano Y, Kanegae H, Bayaraa N, Kishi S, Nagasu H, Nakano T, Wada J, Maruyama S, Nakagawa N, Tamura K, Yokoo T, Yanagita M, Narita I, Yamagata K, Wada T, Tsuruya K, Nakashima N, Isaka Y, Nangaku M, Kashihara N, Okada H; J-CKD-DB study collaborative.：Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.Sci Rep. 14(1):11481, 2024
  11. Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashihara N, Otomo T.：A case series of Fabry diseases with CKD in Japan.Clin Exp Nephrol. 28(5):404-408, 2024
  12. Kitaoka K, Yano Y, Nagasu H, Kanegae H, Chishima N, Akiyama H, Tamura K, Kashihara N.：Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.BMJ Open Diabetes Res Care. 12(3):e004115, 2024
  13. Okada H, Ono A, Tomori K, Inoue T, Hanafusa N, Sakai K, Narita I, Moriyama T, Isaka Y, Fukami K, Itano S, Kanda E, Kashihara N.：Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.PLoS One. 19(4):e0302101, 2024
  14. Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashihara N.：New marker for chronic kidney disease progression and mortality in medical-word virtual space. Sci Rep. 14(1):1661, 2024
  15. Nangaku M, Herrington WG, Goto S, Maruyama S, Kashihara N, Ueki K, Wada J, Watada H, Nakashima E, Lee R, Massey D, Mayne KJ, Tomita A, Haynes R, Hauske SJ, Kadowaki T. Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.：Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.Clin Exp Nephrol. 28(6):588-595, 2024
  16. Yamamoto T, Kasahara M, Ueshima K, Uemura S, Kashihara N, Kimura K, Konta T, Shoji T, Mima A, Mukoyama M, Saito Y.：Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.Clin Exp Nephrol. 28(8):764-772, 2024
  17. Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashihara N.：Mathematical expansion and clinical application of chronic kidney disease stage as vector field. PLoS One. 19(3):e0297389, 2024
  18. Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J.：Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.Kidney Int. 105(1):189-199, 2024
  19. Kotwal SS, Perkovic V, Jardine MJ, Kim D, Shah NA, Lin E, Coggan S, Billot L, Vart P, Wheeler DC, de Boer IH, Zhang H, Hou FF, Sugawara Y, Marion J, Lewis RJ, Berry LR, McGlothlin A, Jha V, De Nicola L, Gorriz JL, Heerspink HJL; GKPTN and CAPTIVATE Investigators.：The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.JAMA Netw Open. 2024 Dec 2;7(12):e2449998, 2024
  20. Umebayashi R, Matsuoka-Uchiyama N, Sugiyama H, Shikata K, Kashihara N, Makino H, Wada J, Uchida HA.：The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan.Diseases. 12(11):268, 2024
  21. Pollock C, Carrero JJ, Kanda E, Ofori-Asenso R, Palmer E, Niklasson A, Linder A, Woodward H, Pentakota S, Garcia Sanchez JJ, Kashihara N, Fishbane S, Pecoits-Filho R, Wheeler DC.：The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD.Am J Nephrol. 55(6):618-628, 2024
  22. Fishbane S, Carrero JJ, Kumar S, Kanda E, Hedman K, Ofori-Asenso R, Kashihara N, Kosiborod MN, Lainscak M, Pollock C, Stenvinkel P, Wheeler DC, Pecoits-Filho R.：Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort.Kidney360. 2024 Jul 1;5(7):974-986, 2024
  23. Heerspink HJL, Perkovic V, Tuttle KR, Pergola PE, Mahaffey KW, Patel UD, Ishida JH, Kuo A, Chen F, Kustra R, Petrovic V, Rossing P, Kashihara N, Chertow GM.：Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.J Am Soc Nephrol. 35(12):1726-1736, 2024
  24. Aoki R, Nihei Y, Matsuzaki K, Suzuki H, Kihara M, Ogawa A, Nishino T, Sanada S, Yokote S, Okabe M, Shirai S, Fukuda A, Hoshino J, Kondo D, Yokoo T, Kashihara N, Narita I, Suzuki Y.：Gross Hematuria after the COVID-19 mRNA Vaccination:
    Nationwide Multicenter Prospective Cohort Study in Japan    Kidney360. 5(9):1322-1332, 2024
  25. Waki K, Nara M, Enomoto S, Mieno M, Kanda E, Sankoda A, Kawai Y, Miyake K, Wakui H, Tsurutani Y, Hirawa N, Yamakawa T, Komiya S, Isogawa A, Satoh S, Minami T, Iwamoto T, Takano T, Terauchi Y, Tamura K, Yamauchi T, Nangaku M, Kashihara N, Ohe K.：Author Correction: Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.NPJ Digit Med. 7(1):155, 2024
  26. Wing-Shing Fung W, Park HC, Hirakawa Y, Arruebo S, Bello AK, Caskey FJ, Damster S, Donner JA, Jha V, Johnson DW, Levin A, Malik C, Nangaku M, Okpechi IG, Tonelli M, Ueda S, Ye F, Suzuki Y, Wang AY; Regional Board and ISN-GKHA Team Authors.：Capacity for the management of kidney failure in the International Society of Nephrology North and East Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).Kidney Int Suppl (2011). 13(1):97-109, 2024
  27. Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N.：Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.Clin Exp Nephrol. 28(2):85-122, 2024
  28. Sugawara Y, Kanda E, Ohsugi M, Ueki K, Kashihara N, Nangaku M.：eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m(2) in the J-DREAMS cohort.Clin Exp Nephrol. 28(2):144-152, 2024
  29. Hirano A, Yamamoto T, Kadoya H.：Never give up! A case of weaning from 40 years of hemodialysis.Ther Apher Dial. 28(4):664-665, 2024

2023年

  1. Rizk DV, Rovin BH, Zhang H, Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J.：Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. Kidney Int Rep. 2023;8(5):968-979.
  2. Kishi S, Nagasu H, Kidokoro K, Kashihara N.：Oxidative stress and the role of redox signalling in chronic kidney disease. Nat Rev Nephrol. 2023.20(2):101-119.
  3. Kidokoro K, Kadoya H, Cherney DZI, Kondo M, Wada Y, Umeno R, Kishi S, Nagasu H, Nagai K, Suzuki T, Sasaki T, Yamamoto M, Kanwar YS, Kashihara N.：Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway. Kidney360. 2023;4(10):1454-1466.
  4. Kurasawa S, Yasuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Wada T, Yamagata K; REACH-J CKD collaborators.：Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study. Hypertens Res. 2023;46(11):2478-2487.
  5. Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T.：Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. Nephrol Dial Transplant. 2023;38(5):1204-1216.
  6. Asahina Y, Sakaguchi Y, Kajimoto S, Hattori K, Oka T, Kaimori JY, Kashihara N, Isaka Y.：A Randomized Controlled Trial of Whole-Body Vibration on Gait Ability and Balance among Older Hemodialysis Patients. Clin J Am Soc Nephrol. 2023;18(1):84-90.
  7. Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N.：Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. 2023.28(2):85-122.
  8. Kanda E, Epureanu BI, Adachi T, Kashihara N.：Machine-learning-based Web system for the prediction of chronic kidney disease progression and mortality. PLOS Digit Health. 2023;2(1):e0000188.
  9. Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J.：Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2023:S0085-2538(23)00754-8.
  10. Sugawara Y, Kanda E, Ohsugi M, Ueki K, Kashihara N, Nangaku M.：eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m2 in the J-DREAMS cohort. Clin Exp Nephrol. 2023;28(2):144-152.
  11. Itano S, Kanda E, Nagasu H, Nangaku M, Kashihara N.：eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database. Clin Exp Nephrol. 2023;27(10):847-856.
  12. Okuda Y, Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Sawanobori T, Taguri M.：The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial. Hypertens Res. 2023;46(2):437-444.
  13. Sugawara Y, Hirakawa Y, Nagasu H, Narita A, Katayama A, Wada J, Shimizu M, Wada T, Kitamura H, Nakano T, Yokoi H, Yanagita M, Goto S, Narita I, Koshiba S, Tamiya G, Nangaku M, Yamamoto M, Kashihara N.：Genome-wide association study of the risk of chronic kidney disease and kidney-related traits in the Japanese population: J-Kidney-Biobank.: J Hum Genet. 2023;68(2):55-64.
  14. Ikeda A, Fujii M, Ohno Y, Godai K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.：Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance.: J Diabetes Investig. 2023;14(6):782-791.
  15. Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Wada J, Sugiyama H, Nakano T, Wada T, Shimizu M, Suzuki H, Komatsu H, Nakashima N, Kitaoka K, Narita I, Okada H, Suzuki Y, Kashihara N.：Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database.: Nephrology (Carlton). 2023;29(2):65-75.
  16. Fujii M, Ohno Y, Ikeda A, Godai K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.：Current evidence and perspectives for hypertension management in Asia
    Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan.:         Hypertens Res. 2023;46(5):1075-1089.
  17. Li Y, Fujii M, Ohno Y, Ikeda A, Godai K, Nakamura Y, Akagi Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.：Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes-Evidence from a large national database in Japan.: PLoS One. 2023;18(12):e0295235.
  18. Hirano A, Kadoya H, Yamanouchi Y, Kishi S, Sasaki T, Kashihara N.：IL-1β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis.: BMC Nephrol. 2023;24(1):374.
  19. Hajime Nagasu, Atsuyuki Tokuyama, Eiichiro Kanda, Seiji Itano, Seiji Kishi, Tamaki Sasaki, Naoki Kashihara.：The Impact of Potassium Binders on Mortality in Patients with Hyperkalemia.: Kidney Dial dialysis. 2023;3(3):244-254.

受賞

2025年

2024年

第27回日本腎臓学会　優秀論文賞　板野　精之
第24回川崎医学会賞　川崎医学会誌論文賞　梅野　怜奈
川崎医科大学　笠岡第一病院　若手研究者学術振興基金　加戸　学

2023年

川崎医科大学　守分記念賞　長洲　一
第7回ポドサイト研究会　最優秀演題賞　城所　研吾
第13回腎不全研究会　特別奨励賞　高須　将伸
第45回日本高血圧学会総会　若手優秀ポスター発表賞　岩倉　主
第53回日本腎臓学会西部学術大会　優秀演題賞　仙田寛武